Atypical antipsychotics in the therapy of bipolar disorders: efficacy and safety

References

• American Psychiatric Association. DSM-IV TR Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol. Psychiatry48,445–457 (2000).
   PubMed Web of Science ®Google Scholar
• ••Original comparison between historicaland current perspectives concerning the prognosis of bipolar disorders.
   Google Scholar
• Tohen M, Goodwin E Epidemiology of bipolar disorder. In: Psychiatric Epidemiology Tsuang MT, Tohen M, Zahner G (Ed.), John Wiley and Sons, New York, USA, 301–316 (1995).
   Google Scholar
• McMahon FJ, Simpson SG, McInnis MG et al. Linkage of bipolar disorder to chromosome 18q and the validity of bipolar II disorder. Arch. Gen. Psychiatry58, 1025–1031 (2001).
   Google Scholar
• Kupfer DJ. Models of bipolar disease and their clinical implications. Biol. Psychiatry 48,428–429 (2000).
   PubMedGoogle Scholar
• Biederman J, Mick E, Faraone SV et al. Pediatric mania: a developmental subtype of bipolar disorder? Biol. Psychiatry 48, 458–466 (2000).
   Google Scholar
• Lewis L. A consumer perspective concerning the diagnosis and treatment of bipolar disorder. Biol. Psychiatry48,442–444 (2000).
   PubMedGoogle Scholar
• •The point of view of the National Depressive and Manic—Depressive Association, USA.
   Google Scholar
• Strakowski SM, DelBello MP, Fleck DE et al. The impact of substance abuse on the course of bipolar disorder. Biol. Psychiatry 48,477–485 (2000).
   PubMed Web of Science ®Google Scholar
• Berk M, Segal J, Leigh J et al. Emerging options in the treatment of bipolar disorders. Drugs 61(10), 1407–1414 (2001).
   Google Scholar
• •Review of current and future therapies of bipolar disorders.
   Google Scholar
• Calabrese JR, Rapport DJ. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder. j Clin. Psychiatry 60 (5), 5–13 (1999).
   Google Scholar
• McElroy SL, Keck PE. Pharmacologic agents for the treatment of acute bipolar mania. Biol. Psychiatry48, 539–557 (2000).
   PubMed Web of Science ®Google Scholar
• ••Rigorous review of therapeutic strategiesin acute bipolar mania.
   Google Scholar
• Nemeroff CB. An ever-increasing Pharmacopeia for the management of patients with bipolar disorder. J. Clin. Psychiatry 61(13), 19–25 (2000).
   Google Scholar
• •Synthetic description of the current therapies in bipolar disorders.
   Google Scholar
• Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol. Psychiatry 48,573–581 (2000).
   PubMed Web of Science ®Google Scholar
• ••Complete review of the issues inpreventive treatment.
   Google Scholar
• Bowden CL, Calabrese JR, McElroy SL et al. Randomised placebo-controlled trial of divalproex versus placebo and lithium in maintenance therapy of bipolar disorder. Arch. Gen. Psychiatry 57,481–489 (2000).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. J Clin. Psychiatry 60,79–88 (1999).
   PubMed Web of Science ®Google Scholar
• Goldberg JF. Treatment guidelines: current and future management of bipolar disorder. Clin. Psychiatry61(13), 12–18 (2000).
   Google Scholar
• •Complete comparison of the most current treatment guidelines, where many therapeutical issues are debated.
   Google Scholar
• Altshuler LL, Post RM, Leverich GS et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am. J Psychiatry152,1130–1138 (1995).
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Hopkins HS. Antipsychotics in bipolar disorder. J Clin. Psychiatry57(9), 49–52 (1996).
   Google Scholar
• Sachs GS, Printz DJ, Kahn DA et al. The Expert Consensus Guideline Series: medication treatment of bipolar disorder 2000. Postgrad. Med. Special issue (Apr), 1–104 (2000).
   Google Scholar
• Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin. Psychiatry 60 (10), 5–14 (1999).
   Google Scholar
• ••Receptor pharmacology review of atypicalagents, with a focus on their differences from conventional antipsychotics and clinical effects.
   Google Scholar
• Gerlach J. Atypical antipsychotics: an inspiring but confusing concept. Psychopharmacology148,1–2 (2000).
   Google Scholar
• •In a short editorial, the author presents his critical point of view concerning the concept of atypical antipsychotics and the sponsored clinical trials conducted with these drugs.
   Google Scholar
• Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl. J Med. 324,746–754 (1991).
   PubMed Web of Science ®Google Scholar
• Westerink BHC, Kawahara Y, De Boer P et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. I Pharmacol. 412 (2), 127–138 (2001).
   Google Scholar
• •Interesting preclinical study.
   Google Scholar
• Audinot V, Newman-Tancredi A, Cussac D et al. Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT) iB and h5-HT1p receptors. Neuropsychopharmacology25(3), 410–422 (2001).
   Google Scholar
• •Interesting preclinical study.
   Google Scholar
• Zeng XP, Le F, Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. j Pharmacol. 321(3), 349–354 (1997).
   Google Scholar
• •Interesting preclinical study.
   Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci. 68,29–39 (2000).
   Google Scholar
• •Exhaustive review of the different potency and sensibility in binding receptors.
   Google Scholar
• Zarate CA. Antipsychotic drug side effect issues in bipolar manic patients. J Clin. Psychiatry 61 (8), 52–61 (2000).
   Google Scholar
• Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr. Scand. 101,416–431 (2000).
   PubMed Web of Science ®Google Scholar
• Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Safety 24(1), 59–74 (2001).
   PubMed Web of Science ®Google Scholar
• ••Most recent and exhaustive review of weight gain in atypical antipsychotic treatment, with focus on the differences between them.
   Google Scholar
• Casey DE. Side effect profiles of new antipsychotic agents. j Clin. Psychiatry 57(11), 40–45 (1996).
   Google Scholar
• Hasan S, Buckley P Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am. J Psychiatry 155(8), 1113–1116 (1998).
   PubMed Web of Science ®Google Scholar
• •Critical review of diagnostic criteria of neuroleptic malignant syndrome with atypical agents.
   Google Scholar
• Banov MD, Zarate CA, Tohen M et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin. Psychiatry 55(7), 295–300 (1994).
   Google Scholar
• Kimmel SE, Calabrese JR, Woyshville MJ et al. Clozapine in treatment-refractory mood disorders. J Clin. Psychiatry55 (9 B), 91–93 (1994).
   Google Scholar
• Zarate CA, Tohen M, Banov MD et al. Is clozapine a mood stabilizer? J Clin. Psychiatry56(3), 108–112 (1995).
   Google Scholar
• Calabrese JR, Kimmel SE, Woyshville MJ et al. Clozapine for treatment-refractory mania. Am.j Psychiatry 153 (6), 759–764 (1996).
   Google Scholar
• Green Al, Tohen M, Patel JK et al. Clozapine in the treatment of refractory psychotic mania. Am. J Psychiatry157, 982–986 (2000).
   PubMed Web of Science ®Google Scholar
• Barbini B, Scherillo P, Benedetti F et al. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int. Clin. Psychopharmacol. 12(2), 109–112 (1997).
   Google Scholar
• Suppes T, Webb A, Paul B et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am.j Psychiatry156(8), 1164–1169 (1999).
   Google Scholar
• Bouchard RH, Demers MF, Simoneau I et al. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin. Psychopharmacol. 21(1), 110–111 (2001).
   Google Scholar
• Dunayevich E, McElroy SL. Atypical antipsychotics in the treatment of bipolar disorder: pharmacological and clinical effects. CNS Drugs13 (6), 433–441 (2000).
   Google Scholar
• ••Exhaustive review of the most recentstudies of atypical antipsychotics treatment in bipolar disorders, with a focus on efficacy and safety.
   Google Scholar
• Esel E, Turan MT, Sofouglu S et al. Improvement of tardive dyskinesia in a bipolar patient with olanzapine. Eur: Psychiatry15,438–439 (2000).
   Google Scholar
• Tollefson GD, Beasly CM, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J Psychiatry154 (4), 457–465 (1997).
   PubMed Web of Science ®Google Scholar
• Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int. Clin. Psychopharmacol. 14(6), 339–343 (1999).
   Google Scholar
• Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Am. J Psychiatry156 (5), 702–709 (1999).
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania. Arch. Gen. Psychiatry57, 841–849 (2000).
   PubMed Web of Science ®Google Scholar
• McElroy SL, Frye M, Denicoff K et al. Olanzapine in treatment-resistant bipolar disorder. J Affect. Disord. 49,119–122 (1998).
   PubMedGoogle Scholar
• Zarate CA, Narendran R, Tohen M et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin. Psychiatry 59(1), 24–28 (1998).
   Google Scholar
• Sanger TM, Tohen M, Jacobs T et al. Olanzapine in the treatment of rapid-cycling bipolar I patients. Eur. NeuropsychopharmacoL 9(5), S246 (1999).
   Google Scholar
• Sharma V, Pistor L. Treatment of bipolar mixed state with olanzapine. .1. Psychiatry Neurosci. 24(1), 40–44 (1999).
   Google Scholar
• Tohen M, Jacobs TG, Timpe TM et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of bipolar disorder. BioL Psychiatry49,110S-111S (2001).
   Google Scholar
• Vieta E, Reinares M, Corbella B et aL Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. .1. Clin. PsychopharmacoL 21(5), 469–473 (2001).
   Google Scholar
• Rothschild AJ, Bates KS, Boehringer KL et al. Olanzapine response in psychotic depression.' Clin. Psychiatry60(2), 116–118 (1999).
   Google Scholar
• Aubry JM, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. Clin. Psychiatry61(9), 649–655 (2000).
   Google Scholar
• •Accurate analysis of the antidepressant effect and the mania-induced risk with olanzapine and risperidone.
   Google Scholar
• Zarate CA, Rothschild A, Fletcher KE et aL Clinical predictors of acute response with quetiapine in psychotic mood disorders. Clin. Psychiatry 61(3), 185–189 (2000).
   Google Scholar
• Schaller JL. Quetiapine for refractory mania in a child. jAm. Acad. Child Adolesc. Psychiatry38,498–499 (1999).
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Brenner R, Alcantara A. Clinical experience with quetiapine in elderly patients with psychotic disorders. .1. Geriatr. Psychiatry NeuroL 13(1), 28–32 (2000).
   Google Scholar
• Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann. Clin. Psychiatry 11(3), 137–140 (1999).
   Google Scholar
• Sajatovic M, Brescan DW, Perez DE et al. Quetiapine alone and added to a mood stabilizer for serious mood disorders. .1. Clin. Psychiatry 62 (9), 728–732 (2001).
   Google Scholar
• Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin. NeuropharmacoL 21,176–180 (1998).
   Google Scholar
• Keck PE, Wilson DR, Strakowski SM et aL Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders. .1. Clin. Psychiatry 56(10), 466–470 (1995).
   Google Scholar
• Jacbsen FM. Risperidone in the treatment of affective and obsessive-compulsive disorder. .1. Clin. Psychiatry56 (9), 423–429 (1995).
   Google Scholar
• Tohen M, Zarate CA, Centorrino F et al. Risperidone in the treatment of mania. .1. Clin. Psychiatry57 (6), 249–253 (1996).
   Google Scholar
• Negrön AE, Leiderman EA, Parkadavil M et aL A naturalistic outcome study of risperidone treatment among state hospital patients. Psych. Services 47(10) 1118–1120 (1996).
   Google Scholar
• Frazier JA, Meyer MC, Biederman J et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. .1. Am. Acad. Child Adolesc. Psychiatry38(8), 960–965 (1999).
   Google Scholar
• Daniel DG, Copeland LE Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. Exp. Opin. Invert. Drugs 9(4), 819–828 (2000).
   Google Scholar
• •Complete review concerning the pharmacological and efficacy, side effect profile of this novel agent.
   Google Scholar
• Schimdt AW, Lebel LA, Howard HR et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. PharmacoL 425(3), 197–201 (2001).
   Google Scholar
• Sprouse JS, Reynolds LS, Braselton JP et aL Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT 1A receptor activation. Neuropsychopharmacology 21 (5), 622–631 (1999).
   Google Scholar
• Rollema H, Lu Y, Schmidt AW et al. 5- HT1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. BioL Psychiatry48, 229–237 (2000).
   PubMed Web of Science ®Google Scholar
• Carnahan RIVI, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy21 (6), 717–730 (2001).
   PubMed Web of Science ®Google Scholar
• •Detailed description of the clinical study conducted up to now and the emerging issues.
   Google Scholar
• Goff DC, Posever T, Herz L et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalised patients with schizophrenia or schizoaffective disorder. .1. Clin. PsychopharmacoL 18(4), 296–304 (1998).
   Google Scholar
• Keck PE, Reeves KR, Harrigan EP et aL Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. .1. Clin. Psychopharmacol. 21(1), 27–35 (2001).
   Google Scholar
• Lesem MD, Zajecka JM, Swift RH et aL Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. .1. Clin. Psychiatry62(1), 12–18 (2001).
   Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 20(5), 491–505 (1999).
   Google Scholar
• Bucley PE Broad therapeutic uses of atypical antipsychotic medications. BioL Psychiatry50,912–924 (2001).
   Google Scholar
• Miller D, Lakshmi NY, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J. Clin. Psychiatry 62 (12), 975–980 (2001).
   Google Scholar
• Brown ES, Thomas NR, Carmody T eta]. Atypical antipsychotics in bipolar and schizoaffective disorders. Pharmacopsychiatry34(2), 80–81(2001).
   Google Scholar
• Guille C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder.' Clin. Psychiatry61 (9), 638–642 (2000).
   Google Scholar
• Berettini WH. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. BioL Psychiatry 48, 531–538 (2000).
   Google Scholar
• •Original approach from a diagnostic perspective, starting from molecular linkage studies.
   Google Scholar
• Post RM. Comparative pharmacology of bipolar disorder and schizophrenia. Schizophrenia Res. 39,153–158 (1999).
   Google Scholar
• •New insights about some neurobiological mechanisms of the two psychoses, starting from a pharmacological approach.
   Google Scholar
• Fitzgerald LW, Deutch AY, Gasich G et al. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15, 2453–2464 (1995).
   PubMed Web of Science ®Google Scholar